FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bogdanovich, S.
Right arrow Articles by Khurana, T. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bogdanovich, S.
Right arrow Articles by Khurana, T. S.
(The FASEB Journal. 2005;19:543-549.)
© 2005 FASEB

Myostatin propeptide-mediated amelioration of dystrophic pathophysiology

Sasha Bogdanovich*, Kelly J. Perkins*, Thomas O. B. Krag*,{dagger}, Lisa-Anne Whittemore{ddagger} and Tejvir S. Khurana*,1

* Department of Physiology and Pennsylvania Muscle Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA;
{dagger} Department of Experimental Medicine, Glostrup Hospital, Glostrup, Denmark; and;
{ddagger} Cardiovascular and Metabolic Disease Department, Wyeth Research, Cambridge, Massachusetts, USA

1Correspondence: Department of Physiology and Pennsylvania Muscle Institute, A-601 Richards Building, University of Pennsylvania School of Medicine, 3700 Hamilton Walk, Philadelphia, PA 19104-6085, USA. E-mail: tsk{at}mail.med.upenn.edu

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this transforming growth factor-ß (TGF-ß) superfamily member negatively regulates muscle growth. Myostatin blockade therefore offers a strategy for reversing muscle wasting in Duchenne’s muscular dystrophy (DMD) without resorting to genetic manipulation. Here, we demonstrate that pharmacological blockade using a myostatin propeptide stabilized by fusion to IgG-Fc improved pathophysiology of the mdx mouse model of DMD. Functional benefits evidenced by specific force improvement, exceeded those reported previously using myostatin antibody-mediated blockade. More importantly, use of a propeptide blockade strategy obviates possibilities of anti-idiotypic responses that could potentially limit the effectiveness of antibody-mediated myostatin blockade strategies over time. This study provides a novel pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD and since it uses an endogenous inhibitor of myostatin should help circumvent technical hurdles and toxicity associated with conventional gene or cell based therapies.


Key Words: DMD • dystroglycan complex • neuromuscular disease • dystrophin • extracellular matrix




This article has been cited by other articles:


Home page
 FASEB J.Home page
M. Nakatani, Y. Takehara, H. Sugino, M. Matsumoto, O. Hashimoto, Y. Hasegawa, T. Murakami, A. Uezumi, S. Takeda, S. Noji, et al.
Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice
FASEB J, February 1, 2008; 22(2): 477 - 487.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. L. Mendias, K. I. Bakhurin, and J. A. Faulkner
Tendons of myostatin-deficient mice are small, brittle, and hypocellular
PNAS, January 8, 2008; 105(1): 388 - 393.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. Xu, K. Chandrasekharan, J. H. Yoon, M. Camboni, and P. T. Martin
Overexpression of the Cytotoxic T Cell (CT) Carbohydrate Inhibits Muscular Dystrophy in the dyW Mouse Model of Congenital Muscular Dystrophy 1A
Am. J. Pathol., July 1, 2007; 171(1): 181 - 199.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
S. Welle, K. Bhatt, C. A. Pinkert, R. Tawil, and C. A. Thornton
Muscle growth after postdevelopmental myostatin gene knockout
Am J Physiol Endocrinol Metab, April 1, 2007; 292(4): E985 - E991.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Amthor, R. Macharia, R. Navarrete, M. Schuelke, S. C. Brown, A. Otto, T. Voit, F. Muntoni, G. Vrbova, T. Partridge, et al.
Lack of myostatin results in excessive muscle growth but impaired force generation
PNAS, February 6, 2007; 104(6): 1835 - 1840.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. D. Rodgers, E. H. Roalson, G. M. Weber, S. B. Roberts, and F. W. Goetz
A proposed nomenclature consensus for the myostatin gene family
Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E371 - E372.
[Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
C. L. Mendias, J. E. Marcin, D. R. Calerdon, and J. A. Faulkner
Contractile properties of EDL and soleus muscles of myostatin-deficient mice
J Appl Physiol, September 1, 2006; 101(3): 898 - 905.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. A. Parsons, D. P. Millay, M. A. Sargent, E. M. McNally, and J. D. Molkentin
Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular Dystrophy
Am. J. Pathol., June 1, 2006; 168(6): 1975 - 1985.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
V. ROSEN
BMP and BMP Inhibitors in Bone
Ann. N.Y. Acad. Sci., April 1, 2006; 1068(1): 19 - 25.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by The Federation of American Societies for Experimental Biology.